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The burden of tobacco dependence can be measured in premature deaths due to accelerated atherosclerotic disease and
cancer, and economic costs of lost productivity and intensified medical care. Smoking cessation efforts have benefited
from continued pharmacologic developments, increased public awareness of stop-smoking programs, aggressive counter-
campaigns to illustrate the toll of cigarette smoking, and recognition of the many primary and secondary effects of
smoking exposure on the general public. Vascular surgeons and interventionalists, as well as vascular medicine specialists,
are uniquely positioned to engage and educate the patient to promote cessation, monitor for continued abstinence, and
assist in efforts to avoid relapses. This article reviews the effects of tobacco dependence on peripheral arterial disease,
perioperative considerations in smokers, as well as common clinical interventions such as counseling and pharmacother-
apy to encourage tobacco cessation. (J Vasc Surg 2010;51:1529-37.)The single greatest opportunity to improve health and
reduce premature deaths is the modification of personal
behavior, as unhealthy behaviors account for nearly 40% of
all deaths in the United States.1 Modification of unhealthy
behaviors has traditionally been viewed with skepticism,
and attempts to change them were considered outside
traditional medical care, at best the purview of a primary
care physician and not a specialist. Perhaps due to med-
ical indifference toward behavior over organic disease,
smoking remains the greatest behavioral cause of death,
and each year tobacco abuse kills 435,000 Americans and
over 10 million persons worldwide.1,2 Related to the
confluence of the 1964 report of the Surgeon General, a
steady stream of population and scientific data demon-
strating early deaths in smokers, and laws to promote
smoke-free places,3,4 the prevalence of smoking in the
United States has declined among men from 57% to 23%
and among women from 34% to 18% for the period of 1955
to 2005.3 Among the factors motivating this decline, the
two greatest are increasing smoke-free public places and
increased taxation of cigarettes.5 Smoking rates have de-
clined in all age groups in the US, except recently among
persons between 18 and 24 in whom the prevalence rose
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doi:10.1016/j.jvs.2009.10.124from 23% in 1991 to 27% in 2000.6 Globally, smoking is
still a common practice, and worldwide estimates of 47% of
men and 12% of women smoke, with the highest rate of
smoking among men in Asia (67% in China, 65% in Korea,
and 53% in Japan).7
Of the current 44.5 million smokers in the United
States, 70% (31 M) claim they would like to quit:8 70% of
smokers visit a physician yearly, and 46% report an attempt
to quit smoking in the past year.8 Yet quit rates are histor-
ically very low, averaging only 2.5% among those attempt-
ing cessation without pharmacotherapy or counseling. If
the quit rate could be increased to 10%, a rate appreciated in
most recent trials, up to 1.1 million premature deaths could
be avoided.9 Most smokers mistakenly believe that stop-
ping smoking is purely a matter of willpower and remain
unaware of effective treatments to promote quitting. It is
incumbent on physicians whom often treat smokers to be
familiar with available therapies to educate patients of their
options for smoking cessation. This review will serve to
provide a knowledge base of adverse effects of smoking on
peripheral artery disease (PAD), practical tools for office-
based encounters, and medical information concerning
available prescription pharmacotherapy to motivate our
patients toward smoking cessation.
EFFECTS OF TOBACCO ON PAD AND AAA
The relationship of smoking and PAD was first de-
scribed by Erb in 1911, reporting intermittent claudica-
tion as three times more common among smokers than
nonsmokers.10 Smoking history carries a much stronger
association with PAD than coronary artery disease
(CAD) as demonstrated in the multiple worldwide epi-
demiological studies and the Framingham Heart
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to a decade earlier in smokers than nonsmokers.15,16 The
severity of PAD tends to increase with the number of
cigarettes smoked.11,17-19 For patients with intermittent
claudication, rapid improvement in incidence of severe
symptoms has been reported with smoking cessation18,19
and measured treadmill walking distance,20 but more mar-
ginal improvement was noted in the Edinburgh Heart
Study (relative risk [RR] of IC 3.7 in smokers vs RR of IC
3.0 in exsmokers), suggesting heterogeneity in the degree
of walking distance improvement after cessation in the large
study population.15
The progression of PAD from asymptomatic to claudi-
cation to ischemic rest pain is strongly associated with
cigarette smoking with a linear relationship to the highest
tertile of pack years of exposure (48 years) yielding an
odds ratio (OR) of 1.6.11-19 For patients with bypass grafts,
the incidence of graft failure is threefold higher in smokers
and can be reduced to that of nonsmokers with smoking
cessation instituted at the time of revascularization.21
This relationship holds for bypass conduits of both
autogenous and prosthetic material. Amputation rates are
also highly correlated with smoking history. For smokers
with critical limb ischemia, the amputation rate was 11% to
23% vs 0% to 10% in nonsmokers.22 For patients with
thromboangiitis obliterans (Buerger’s disease), the pre-
sumed pathogenesis hinges on causative components in the
tobacco product, thus smoking cessation is a cornerstone of
treatment.23
Tobacco smoking is a specific risk factor for abdominal
aortic aneurysm (AAA) prevalence, incidence, and progres-
sion.24 Over 90% of all AAA patients have a history of
tobacco abuse, and nearly half are active smokers at the time
of diagnosis.25 The risk of AAA development is more
closely related to smoking history than any other tobacco-
related disease except lung cancer.26 Indeed, the risk of
AAA in individuals who have ever smoked is 2.5 times
greater than the risk for coronary heart disease.26 The
largest trial examining status and progression of AAA is the
United Kingdom Small Aneurysm Trial. In their 1743
patients followed up to 7 years, self-reported cigarette
smoking was associated with an increased growth rate of
0.4 mm per year, greater than the mean growth rate of
aneurysms 5.5 cm of 2.6 to 3.2 mm/y.27 Smoking ces-
sation should be considered a major component of surveil-
lance and nonoperative management protocols.
PERIOPERATIVE MANAGEMENT
OF SMOKERS
Current smoking increases the risk for postoperative
pulmonary complications by threefold, and such risk does
not require concomitant chronic lung disease.28-30 Three
studies28-30 analyzed the risk of postoperative pulmonary
complications attributable to smoking and reported the
same counterintuitive result: recent quitters have a higher
rate of pulmonary morbidity than do current smokers, with
an RR up to 6.7 for smokers who recently stopped.28Patients who quit smoking closest to the date of the surgeryhad the highest rate of pulmonary complications.31 Naka-
gawa et al reported a higher pulmonary complication rate
for those who quit smoking within 4 weeks of surgery
(54%) than among current smokers (43%) or those who
were smoking-abstinent for more than 4 weeks preopera-
tively (35%).31 The exact mechanism for this seemingly
paradoxical clinical relationship could relate to the clinical
observation of increased sputum production and expecto-
ration in the months after cigarette cessation or a selection
bias that those with more lung disease were more likely to
attempt cessation before surgery. Nonetheless, patients
should be strongly encouraged to stop smoking 1 to 2
months before major surgery when practical.
INITIAL APPROACH TO SMOKING CESSATION
In the past, a failure to initiate a conversation concern-
ing tobacco abuse could have been attributable to a lack of
effective treatments. Only 20% of smokers will ask for help
with tobacco cessation, and for those who attempt quitting
tobacco use without assistance, only 10% will be effective
over the long term.32 Recent research has clarified the
addictive nature of nicotine, aligning the dependence as
comparable to the dependence caused by opiates, cocaine,
or other illicit drugs.33 Given the ongoing risk for major
cardiovascular events as defined in population-based stud-
ies, repeated clinical interventions to address chronic users
and relapses seems warranted. Effective pharmacologic and
counseling strategies are now the pillars of tobacco cessa-
tion programs, and taken in combination can achieve the
highest rates of smoking cessation. Indeed, even a brief
period of counseling (3 minutes or less), doubles the ces-
sation rate compared with simple advising to stop smok-
ing.34,35
Brief clinical interventions can be used with three cat-
egories of patients, as assigned by the available Clinical
Practice Guideline for Treating Tobacco Use and Depen-
dence:8
1. Current tobacco users now willing to make a quit at-
tempt
2. Current tobacco users unwilling to make a quit attempt
3. Former tobacco users who have recently quit
The strategies for each group differ significantly in
content and will be addressed separately.
Current tobacco users now willing to make a quit
attempt. Current guidelines urge clinicians to provide
both pharmacotherapy and counseling for every patient
willing tomake a quit attempt.8 Themajor steps in the brief
encounter for this category are the 5 As: (1) ask is he or she
uses tobacco products, (2) advise them to quit, (3) assess
willingness to quit, (4) assist with pharmacotherapy or
counseling, and (5) arrange follow-up to prevent relapse
(Fig 1). Optimal implementation of the intervention can be
bolstered by an office-based system that documents every
patient’s smoking status before the provider sees the patient
and thus reminds the provider to address smoking cessa-
tion, in effect elevating smoking status to a line item
neighbor to standard vital signs. Such programmatic addi-
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physician will intervene.8,36 Adoption of standard practice
guidelines across the state of Wisconsin resulted in 77% of
smokers being queried about tobacco use and 61% were
advised to quit.37
For the patient unwilling to make a quit attempt at
this time. Patients who are unwilling to consider smoking
cessation may lack information about the harmful effects of
smoking, lack financial resources, or may be frustrated by
previous quit failures.38 These patients will respond poorly
to direct confrontation and argument and the best motiva-
tor is an empathic and supportive tone. By identifying the
many treatment choices and identifying prior successes in
behavior modification, an effective clinical intervention can
be assembled.34,39 The major steps to address for patients
in this category are the 5 Rs:8 relevance (why quitting is
sk
to quit at every visit.
to Quit Tobacco
The 5 ’s
dvise
to quit tobacco at every visit.
ssess
willingness to quit at every visit.
ssist
quitting within 2 weeks with
pharmacotherapy or counseling.
rrange
follow-up contact in 1st week
after quitting.
A
A
A
A
A
A
Fig 1. The five As of the brief clinical encounter. These basic
considerations and queries can initiate a discussion regarding
smoking cessation in any patient-doctor setting. Such brief clinical
interventions are associated with an increased rate of smoking
cessation.relevant to their current health scenario), risks (of contin-ued smoking to their current health), rewards (of cessation
both in the short-term and long-term), roadblocks (help
patient identify barriers to quitting, eg social situations,
withdrawal symptoms), and repetition (most patients need
multiple quit attempts) (Fig 2).
For the patient who has recently quit. Relapses are
not uncommon in patients who have successfully quit
tobacco dependence, and although most relapses occur
early,40-41 some patients will resume tobacco products
months to years after the quit date.42 Withdrawal symp-
toms often peak 1 to 3 weeks after quitting, so nicotine
elevance
why quitting is important to them.
(second hand exposure, overall health, etc.)
to the Patient
Unwilling to Quit
Tobacco
The 5 ’s
isks
negative consequences of
ongoing habit.
ewards
benefits of tobacco cessation.
oadblocks
identify impediments to quitting.
(withdrawal symptoms, fear, weight gain)
epetition
repeat every time the patient
comes to the clinic.
R
R
R
R
R
R
Fig 2. The five Rs of the brief clinical encounter. For the patient
unwilling to consider smoking cessation, assessment of the pa-
tient’s understanding of the risks of tobacco usage and benefits of
smoking cessation is critical. The five Rs provide a basic assessment
in any patient-doctor setting.replacement therapies (NRTs) should account for appro-
been
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even a single puff increases the likelihood of a full relapse. In
general, relapse prevention includes two components: en-
gage them to note their perceived benefits of cessation and
address any perceived threats to abstinence. For the latter,
this may include appropriate medication for mood distur-
bance or withdrawal symptoms and efforts at further sup-
portive counseling for cessation. Weight gain may also be a
cause of relapse, especially in women, and averages 5 to 10
lbs (2.3-4.5 kg).43 Large weight gains are uncommon but
are more likely in nonwhites, women, and heavy smokers
than other groups.44 Pharmacotherapy, particularly with
bupropion or nicotine gum (but not the patch) temporarily
reduced weight gain after smoking cessation, but only
during the period of administration, and thus exercise
should be encouraged also.45-47
COUNSELINGANDBEHAVIORAL
MODIFICATION
Cognitive behavioral methods are the pillars of most
counseling programs and can be offered by trained coun-
selors, psychologists, or clinicians. Smokers can learn to
identify environmental and social cues which motivate their
smoking and use cognitive and behavioral methods to
break the link between the cue and smoking.48 They can
also learn stress management, nicotine withdrawal symp-
toms, and coping strategies to quit rate and prevent relapse.
Counseling can be delivered in person or over the phone
with similar efficacy.8 Group or individual therapy is effec-
tive when provided by trained counselors and includes
repeated contact over a period of at least four weeks.8,49
Overall efficacy of smoking counseling programs increases
with more time spent in counseling sessions, with at least
30 minutes total time spent in direct contact and assess-
Table I. Nicotine replacement pharmacotherapy
Drug Precautions Adverse effects
Nicotine gum ACSa Mouth irritation
Nicotine inhaler ACS* Mouth irritation
Nicotine nasal spray ACSa Nasal irritation
Nicotine patch ACSa Insomnia, skin irritation
aThe safety of NRT within 2 weeks of an acute coronary syndrome has not
Table II. Non-nicotinic pharmacotherapy
Drug Precautions A
Buproprion SR (Wellbutrin SR) History of seizures Insom
Varenicline (Chantix) History of neuro-
psychiatric disorders
Nause
heament.8Self-help materials for smoking cessation have little
efficacy when used alone,49 but are encouraged as part of a
comprehensive intervention including counseling and
pharmacotherapy. Smoking counseling strategies and state-
by-state locations are found in abundance on the Internet
at the American Lung Society (www.lungusa.org), Ameri-
can Cancer Society (www.cancer.org), stop smoking re-
sources at the American Legacy Foundation Truth Cam-
paign (www.americanlegacy.org), and at www.smokefree.
gov.
PHARMACOTHERAPY
Every patient making an attempt at smoking cessation
should be offered pharmacologic therapies to improve their
chances of success. A few selected populations may not
warrant prescription based on medical safety concerns or
lack of proven benefit in clinical trials, such as those smok-
ing fewer than 10 cigarettes/day, pregnant/breastfeeding
women, and adolescent smokers.8 Many effective pharma-
cotherapies now exist for the treatment of tobacco depen-
dence. First line therapies approved by the Food and Drug
Administration (FDA) include six agents: sustained-release
bupropion (Wellbutrin SR), varenicline (Chantix), and
four NRTs. Two second line therapies have also been
shown to be efficacious: clonidine and nortryptyline, but
are not FDA approved for the tobacco cessation indication.
Nicotinic and non-nicotinic treatment regimens are sum-
marized in Tables I and II.
NRTs. The majority of smokers sustain dependence-
producing levels of nicotine intake, yielding the craving of
tobacco products.49 Nicotine addiction leads to alteration
of brain structure with nicotinic receptor upregulation,
changes in brain activity evidenced by altered regional
glucose metabolism, and cognitive effects that patients
Dosage Duration
-24 cigarettes: 2-mg gum, up to 24 pieces/d
25 cigarettes: 4-mg gum, up to 24 pieces/d
Up to 12 wk
Up to 12 wk
-16 cartridges/d Up to 6 mo
-40 doses/d 3-6 mo
1 mg/24 h
4 mg/24 h
mg/24 h
5 mg/16 h
4 wk, then
2 wk, then
2 wk, stop
8 wk
established and should be used with caution.
e effects Dosage Duration
dry mouth 150 mg qAM for 3 d, the 150 mg BID 7-12 wk
omnia, .5 mg daily  3 d, then
.5 mg BID  4 d, then
1 mg BID  12 wks
12 wk1

6
8
2
1
7
1dvers
nia,
a, ins
dacherely on such as mood and sleep control.50 The tobacco
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behaviors and forms the basis of the physical addiction to
the smoking product as a vessel of nicotine delivery. The
NRTs enable the person to abstain from tobacco by
replacing the nicotine derived from their tobacco prod-
uct use, albeit none of the NRTs can elevate blood
nicotine levels as quickly as inhaled cigarette smoke (see
Fig 3).46 There are at least three mechanisms by which
NRTs can aid smoking cessation efforts; first, physical
withdrawal symptoms may be reduced, NRTs may also
reduce the addiction enforcing effects of tobacco-
derived nicotine, and lastly by avoiding the mood distur-
bances and attention states of withdrawal.51
The average systemic nicotine intake from cigarettes is
30 mg/day.52 Nicotine gum, for example, if provided in
the usual 2- or 4-mg tablet and taken on schedule, usually
provides 10mg or 20mg, respectively. Thus, most smokers
do not match the daily nicotine levels achieved through
smoking.53 Increased dose schedules are not strictly ap-
proved by the FDA, but combining NRT products such as
the patch with gum or nasal spray was associated with
higher cessation successes.8,48,54 NRT appears safe in most
patients, including those with cardiovascular disease and
stable angina, and is now approved for over-the-counter
sale. The safety of NRT has not been studied in patients
with unstable angina or myocardial infarction within 2
weeks of planned treatment.55,56 Thus, for those inpatients
with nicotine dependence admitted for acute coronary
syndrome, NRTs should be used with caution. In a ran-
domized, controlled trial, the results of the four NRT
products were compared. After 12 weeks of therapy, effi-
cacy was similar (20%-24%), but the compliance varied
among the groups widely, with the highest use noted in the
patch (82%), intermediate in the gum (38%), and lowest in
nasal spray (15%) and vapor inhaler (11%).57 The expected
12-month abstinence rate for NRT is 10%-16%.50
Since 1996, NRTs have been available as an over-the-
counter purchase. Pharmaceutical companies have marketed
the products widely, and a 6-week course of the NRTs can
cost $150 for a patch to $300 for gum, but most insurance
companies support themas a prescription benefit, recognizing
Fig 3. Kinetics of nicotine absorption. Venous blood c
duced with permission from Garrett, BE.50the long-term savings of smoking cessation in downstreammedical costs.58,59 In an analysis of NRT use from 1992 to
1999 in California,60 NRTs increased 3.6-fold, yet the me-
dian treatment period was only 14 days, much less than
recommended. This further suggests that NRTmonotherapy
in the absence of clinician guidance in tobacco cessation is not
likely to be effective. Among those patients in whom NRT
cost was covered by insurance payment, 40% used it for 6
weeks or longer vs only 21% of those who paid for NRT
over-the-counter. The smoking cessation advantage was only
observed in the cohort of patients before 1996 and not
thereafter, suggesting a lack of a regulated period of use and
lack of concomitant counseling abrogated any advantage to
sole NRT.60 Current guidelines clearly demonstrate a place
for NRTs in smoking cessation efforts to reduce withdrawal
symptoms, but combination therapy with non-nicotinic med-
ications (and behavioral counseling) is most efficacious at
producing long-term quitting.8
Sustained-release bupropion (Wellbutrin SR).
Bupropion SR is the first non-nicotine medication to gain
FDA approval for use as a smoking cessation medication. It is
available by prescription only, initially in 1989 as an antide-
pressant, but after anecdotal reports of successful quit at-
tempts by smokers taking the drug for depression, it was
reformulated in the SR form in 1997.61,62 The mechanism of
action of bupropion is uncertain but appears to be mediated
by its ability to block reuptake of dopamine.63 This reduces
nicotine craving and anecdotally also appears to create taste
aversion. Bupropion can lower the threshold for seizure and is
contraindicated in patients with a history or seizure or risk for
seizure.47 The most common reported side effects are sleep
disturbance and dry mouth (30% for both).64
The efficacy of bupropion for smoking cessation when
combined with counseling has been proven in randomized,
controlled trials.64-66 Bupropion treatment (vs placebo)
combined with weekly therapy during treatment can lead to
smoking cessation in up to 40% of patients, with 1-year
abstinence rates of 23%.64 There exists a stepwise increase
in abstinence rates with more aggressive dosing schedules.
After 7 weeks of treatment, the cessation rate was 19% in
placebo, 28% in the 100-mg group, 38% in the 150-mg
group, and 44% in the 300-mg group (P  .001).64 Inter-
ntrations for various nicotine delivery products. Repro-onceestingly, the mean absolute weight gain was inversely pro-
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in the 300-mg group.64 Combining bupropion and NRTs
can result in significantly improved smoking cessation rates
than using either product alone (abstinence rates of 16% in
the patch alone vs 30% in those given the patch and
bupropion), and reported withdrawal symptoms and
weight gain were significantly lessened in combination
therapy schedules.65 In examination of depressive symp-
toms, patients while taking bupropion had significantly
greater reductions in depression scores than placebo, al-
though this effect was lost in 4-month follow-up after the
treatment interval stopped.66 Many patients will remain on
bupropion indefinitely for the favorable mood and cogni-
tive changes, even once tobacco cessation has been af-
firmed. Bupropion treatment is discontinued by 10% to
15% of patients for side effects, with the most common side
effects leading to treatment cessation being insomnia and
headache (42% and 25%, respectively), although similar
adverse events can be appreciated in placebo patients.
Varenicline (Chantix). Nicotine dependence is be-
lieved to be mediated by activation of the 42 nicotinic
acetylcholine receptor in the ventral tagmental area of the
brain, and the 42 receptor density has been proven to be
much higher in smokers.67,68 Varenicline functions as a
partial agonist, theoretically relieving withdrawal symp-
toms while blocking further nicotine binding competi-
tively.69 Smoking 1 to 2 puffs of a cigarette resulted in
50% receptor occupancy lasting for 3.1 hours after smok-
ing. A full cigarette results in 88% receptor occupancy and is
associated with reduced craving.70 The efficacy of vareni-
cline to promote smoking cessation was demonstrated in a
randomized, controlled trial comparing varenicline vs bu-
propion SR or placebo.71
During 12 weeks of treatment with 1 mg of varenicline
twice daily, combined with weekly counseling, 43% of
patients were abstinent, vs 30% in the bupropion and 18%
in placebo groups. During the next year, abstinence was
maintained in 23% of varenicline and 15% of bupropion
users and only 10% in placebo-treated subjects. Thus, the
odds of quitting smoking were significantly greater with
varenicline than bupropion (OR, 1.90) or placebo (OR,
3.85).71 In a meta-analysis of available pharmacotherapies
for smoking cessation (NRTs and non-nicotinic medica-
tions),72 all therapies were better than placebo; in the trials
of varenicline that included bupropion in the control arm,
varenicline was found superior (OR, 2.18; CI 1.09-4.08).
The most common reported side effects of varenicline
in its comparative trial were nausea, abnormal dreams,
insomnia, and headache, although the latter two were
similarly appreciated in the placebo arm.71 A growing num-
ber of reported adverse events, the most reports of any drug
in the USA for the fourth quarter of 2007, in patients
taking varenicline prompted the FDA to review all events
since varenicline approval in 2006.72 After review, the FDA
alert advised consumers and physicians about psychiatric
symptoms that included “changes in behavior, agitation,
suicidal ideation, attempted, and completed suicide.” The
FDA alert provided no data about similar events amongother smokers to derive a denominator. Similar events were
not appreciated in the approval study,71 and likely under-
score the fact that most cessation trials exclude patients
with any prior history of psychiatric condition or use of any
concomitant psychologically active drugs.72 The Institute
for Safe Medication Practice has recommended physicians
exercise caution in the use of varenicline in persons in
whom the risk of accident is high, such as those operating
mass transit vehicles, trains, planes, or heavy machinery or
life-sustaining devices.73 Specific drug interactions for
varenicline which potentiate neuropsychiatric events have
not been identified, but multivitamins and cholesterol-
lowering medications seem unlikely suspects.73
THE “TEACHABLE MOMENT”
As an outpatient, physician advice alone and frequent
follow-up achieves 1-year smoking cessation rates of ap-
proximately 5% compared with only 0.1% in those attempt-
ing to quit without physician intervention.74 Inpatient
hospitalization for an acute cardiovascular event results in
abrupt abstinence and a “teachable moment” for smoking
cessation. Unfortunately, at least 40% of smokers resume
smoking in the year following myocardial infarction, de-
spite intensive intervention.74,75 Nonetheless, herein lies
evidence of the powerful motivation by an acute illness or
cardiovascular event to promote smoking cessation, dem-
onstrated by the fact that 1-year cessation rates double the
outcomes of aforementioned cessation medication trials.
Depressive symptoms in hospitalized patients contribute to
some of these smoking cessation failures, and affective
disorders are more likely in smokers than in nonsmokers.76
Patients with depression are less likely to follow recommen-
dations to reduce cardiac risk such as exercise, taking med-
ications, and attending rehabilitation.77-79 Scored on a
depressive index, 30% of the score is attributable to nicotine
withdrawal symptoms, suggesting moderation of those
symptomsmay yield improved cessation rates.80 As vascular
surgeons, it is critically important to take the inpatient
opportunity to identify tobacco-dependent patients who
are at risk for relapse to smoking and address depressive
symptoms and provide follow-up both for the vasculature
and stop-smoking effort. The “teachable moment” to ed-
ucate and discuss relapse intervention can take our inpatient
population toward a 12-month cessation rate of 50%.76
The long-term benefit of smoking cessation on cardio-
vascular risk suggests a 36% reduction in mortality risk.81 In
women, the excess risk of vascular mortality imparted by
smoking appears to be eliminated rapidly (2 years) upon
cessation, contrary to prior estimates suggesting longer
intervals to assume general population estimates.82 The
reduction inmortality due to cardiovascular disease exceeds
the benefits of other preventative therapies such as use of
statins (29%), aspirin (15%), and -blockers (23%).83-85
Smoking cessation is cost effective, and Medicare now
allows reimbursement for smoking cessation counseling to
all clinicians under CPT 99406 for3 and10 minutes of
counseling ($40.05 allowable) and CPT 99407 for 10
minutes ($76.50 allowable).
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Tobacco-related deaths number 400,000 annually in
the United States and 8.6 million suffer tobacco-induced
illness, and there are 4.8 million deaths worldwide, thus
making tobacco use the world’s leading cause of prevent-
able death. Interventions to promote smoking and tobacco
product cessation should be considered a standard of good
practice. Tobacco dependence is a chronic condition, but
the evidence suggests safe and effective medications are
available to help aid patients in their quit attempts. Every
patient who uses tobacco should be offered at least one of
these treatments in the setting of a brief clinical encounter,
whether as an inpatient or outpatient. Counseling should
provide strategies to address withdrawal symptoms and
educate to prevent relapses, while being provided in suffi-
cient intensity and follow-up over time. Vascular specialists
should engage in a comprehensive approach to promote
smoking cessation in their patients. Now is the time to
engage our patients, as the current era presents a unique
intersection of new medications and increased availability
of stop-smoking resources in the wake of the Master Set-
tlement with the tobacco industry.
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